by Peter Ciszewski | Dec 16, 2021
Jerry Vockley, MD, PhD, Head of the Division of Medical Genetics at UPMC Children’s Hospital of Pittsburgh, provides an overview of phenylketonuria (PKU). As Dr. Vockley explains, PKU is a rare genetic metabolic disorder that results in reduced activity of...
by Peter Ciszewski | Dec 15, 2021
Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope Cancer Center, discusses the updated results from the MonumenTAL-1study testing talquetamab relapsed/refractory multiple myeloma. These results...
by Peter Ciszewski | Dec 14, 2021
Dinesh Khanna, MD, Professor of Rheumatology and Medicine at the University of Michigan, discusses diffuse cutaneous systemic sclerosis (dcSSc) and how these patients are typically treated. dcSSc is a subtype of systemic scleroderma (also known as systemic...
by Peter Ciszewski | Dec 14, 2021
Thihan Padukkavidana, PhD, from Takeda Oncology, discusses post-hoc analysis data on the efficacy and safety of ponatinib in chronic-phase chronic myeloid leukemia (CML) patients. This data was presented at the American Society of Hematology Annual Meeting...
by Peter Ciszewski | Dec 10, 2021
The U.S. Food and Drug Administration (FDA) has approved the use of Cutaquiq [immune globulin, subcutaneous (human)-hipp, 16.5% Solution] to treat children age 2 and older with primary humoral immunodeficiency (PI). The FDA previously approved the medication for...
